1. Alberta Blue Cross. (2005). Alberta health and wellness drug benefit list, 2005. Edmonton: Alberta Blue Cross. Retrieved September, 2005, at http://www.ab.bluecross.ca/dbl/publications.html.
2. Bargman J.M., Bick J., Cartier P., Dasgupta M.K., Fine A., Lavoie S.D., Spanner E., Taylor P.A. (1999) Guidelines for adequacy and nutrition in peritoneal dialysis. Journal of the American Society of Nephrology 10(Suppl 13): S311–S321
3. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., Varet B., Mayeux P. (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New England Journal of Medicine 346: 469–475
4. Churchill D.N., Blake P.G., Jindal K.K, Toffelmire E.B., Goldstein M.B. (1999) Clinical practice guidelines for initiation of dialysis. Journal of the American Society of Nephrology 10(Suppl 13): S289–S291
5. CIHI. (2002). From perceived surplus to perceived shortage: What happened to Canada’s physician workforce in the 1990’s? Ottawa: Canadian Institute for Health Information.